South Korea: These 43 Drugs Face Patent Expirations and Generic Entry From 2023 - 2024
DrugPatentWatch® Estimated Loss of Exclusivity Dates in South Korea
The content of this page is licensed under a Creative Commons Attribution 4.0 International License.
Generic Entry Dates in Other Countries
Friedman, Yali, "South Korea: These 43 Drugs Face Patent Expirations and Generic Entry From 2023 - 2024" DrugPatentWatch.com thinkBiotech, 2023 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can VIBATIV (telavancin hydrochloride) generic drug versions launch?
Generic name: telavancin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 22, 2023
Generic Entry Controlled by: South Korea Patent 101,166,250
VIBATIV is a drug marketed by Cumberland Pharms. There are two patents protecting this drug.
This drug has one hundred and twenty-eight patent family members in thirty-five countries.
See drug price trends for VIBATIV.
The generic ingredient in VIBATIV is telavancin hydrochloride. One supplier is listed for this generic product. Additional details are available on the telavancin hydrochloride profile page.
When can VIBATIV (telavancin hydrochloride) generic drug versions launch?
Generic name: telavancin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 22, 2023
Generic Entry Controlled by: South Korea Patent 20,060,094,082
Patent Title: HYDROCHLORIDE SALTS OF A GLYCOPEPTIDE PHOSPHONATE DERIVATIVE
VIBATIV is a drug marketed by Cumberland Pharms. There are two patents protecting this drug.
This drug has one hundred and twenty-eight patent family members in thirty-five countries.
See drug price trends for VIBATIV.
The generic ingredient in VIBATIV is telavancin hydrochloride. One supplier is listed for this generic product. Additional details are available on the telavancin hydrochloride profile page.
When can VIBATIV (telavancin hydrochloride) generic drug versions launch?
Generic name: telavancin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 22, 2023
Generic Entry Controlled by: South Korea Patent 20,120,037,025
Patent Title: HYDROCHLORIDE SALTS OF A GLYCOPEPTIDE PHOSPHONATE DERIVATIVE
VIBATIV is a drug marketed by Cumberland Pharms. There are two patents protecting this drug.
This drug has one hundred and twenty-eight patent family members in thirty-five countries.
See drug price trends for VIBATIV.
The generic ingredient in VIBATIV is telavancin hydrochloride. One supplier is listed for this generic product. Additional details are available on the telavancin hydrochloride profile page.
When can DUETACT (glimepiride; pioglitazone hydrochloride) generic drug versions launch?
Generic name: glimepiride; pioglitazone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 31, 2023
Generic Entry Controlled by: South Korea Patent 100,952,090
DUETACT is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-nine patent family members in thirty-one countries. There has been litigation on patents covering DUETACT
See drug price trends for DUETACT.
The generic ingredient in DUETACT is glimepiride; pioglitazone hydrochloride. There are sixteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the glimepiride; pioglitazone hydrochloride profile page.
When can DUETACT (glimepiride; pioglitazone hydrochloride) generic drug versions launch?
Generic name: glimepiride; pioglitazone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 31, 2023
Generic Entry Controlled by: South Korea Patent 20,060,061,383
Patent Title: SOLID PREPARATION COMPRISING AN INSULIN SENSITIZER, AN INSULIN SECRETAGOGUE AND A POLYOXYETHYLENE SORBITAN FATTY ACID ESTER
DUETACT is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-nine patent family members in thirty-one countries. There has been litigation on patents covering DUETACT
See drug price trends for DUETACT.
The generic ingredient in DUETACT is glimepiride; pioglitazone hydrochloride. There are sixteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the glimepiride; pioglitazone hydrochloride profile page.
When can DUETACT (glimepiride; pioglitazone hydrochloride) generic drug versions launch?
Generic name: glimepiride; pioglitazone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 31, 2023
Generic Entry Controlled by: South Korea Patent 20,100,012,105
Patent Title: SOLID PREPARATION COMPRISING AN INSULIN SENSITIZER, AN INSULIN SECRETAGOGUE AND A POLYOXYETHYLENE SORBITAN FATTY ACID ESTER
DUETACT is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-nine patent family members in thirty-one countries. There has been litigation on patents covering DUETACT
See drug price trends for DUETACT.
The generic ingredient in DUETACT is glimepiride; pioglitazone hydrochloride. There are sixteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the glimepiride; pioglitazone hydrochloride profile page.
When can KUVAN (sapropterin dihydrochloride) generic drug versions launch?
Generic name: sapropterin dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 17, 2023
Generic Entry Controlled by: South Korea Patent 20,070,005,550
Patent Title: METHODS AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS
KUVAN is a drug marketed by Biomarin Pharm. There are ten patents protecting this drug and three Paragraph IV challenges.
This drug has one hundred and fourteen patent family members in twenty-six countries. There has been litigation on patents covering KUVAN
See drug price trends for KUVAN.
The generic ingredient in KUVAN is sapropterin dihydrochloride. There are three drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the sapropterin dihydrochloride profile page.
When can OSMOPREP (sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate) generic drug versions launch?
Generic name: sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 19, 2023
Generic Entry Controlled by: South Korea Patent 101,268,559
OSMOPREP is a drug marketed by Salix Pharms. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has twenty-nine patent family members in eleven countries.
See drug price trends for OSMOPREP.
The generic ingredient in OSMOPREP is sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate. There are one thousand four hundred and seventy-two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate profile page.
When can OSMOPREP (sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate) generic drug versions launch?
Generic name: sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 19, 2023
Generic Entry Controlled by: South Korea Patent 101,323,628
OSMOPREP is a drug marketed by Salix Pharms. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has twenty-nine patent family members in eleven countries.
See drug price trends for OSMOPREP.
The generic ingredient in OSMOPREP is sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate. There are one thousand four hundred and seventy-two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate profile page.
When can OSMOPREP (sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate) generic drug versions launch?
Generic name: sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 19, 2023
Generic Entry Controlled by: South Korea Patent 101,495,690
OSMOPREP is a drug marketed by Salix Pharms. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has twenty-nine patent family members in eleven countries.
See drug price trends for OSMOPREP.
The generic ingredient in OSMOPREP is sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate. There are one thousand four hundred and seventy-two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate profile page.
When can OSMOPREP (sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate) generic drug versions launch?
Generic name: sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 19, 2023
Generic Entry Controlled by: South Korea Patent 20,060,114,342
Patent Title: COLONIC PURGATIVE COMPOSITION WITH SOLUBLE BINDING AGENT
OSMOPREP is a drug marketed by Salix Pharms. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has twenty-nine patent family members in eleven countries.
See drug price trends for OSMOPREP.
The generic ingredient in OSMOPREP is sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate. There are one thousand four hundred and seventy-two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate profile page.
When can OSMOPREP (sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate) generic drug versions launch?
Generic name: sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 19, 2023
Generic Entry Controlled by: South Korea Patent 20,110,098,015
Patent Title: COLONIC PURGATIVE COMPOSITION WITH SOLUBLE BINDING AGENT
OSMOPREP is a drug marketed by Salix Pharms. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has twenty-nine patent family members in eleven countries.
See drug price trends for OSMOPREP.
The generic ingredient in OSMOPREP is sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate. There are one thousand four hundred and seventy-two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate profile page.
When can OSMOPREP (sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate) generic drug versions launch?
Generic name: sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 19, 2023
Generic Entry Controlled by: South Korea Patent 20,120,045,015
Patent Title: COLONIC PURGATIVE COMPOSITION WITH SOLUBLE BINDING AGENT
OSMOPREP is a drug marketed by Salix Pharms. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has twenty-nine patent family members in eleven countries.
See drug price trends for OSMOPREP.
The generic ingredient in OSMOPREP is sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate. There are one thousand four hundred and seventy-two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate profile page.
When can OSMOPREP (sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate) generic drug versions launch?
Generic name: sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 19, 2023
Generic Entry Controlled by: South Korea Patent 20,130,048,790
Patent Title: COLONIC PURGATIVE COMPOSITION WITH SOLUBLE BINDING AGENT
OSMOPREP is a drug marketed by Salix Pharms. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has twenty-nine patent family members in eleven countries.
See drug price trends for OSMOPREP.
The generic ingredient in OSMOPREP is sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate. There are one thousand four hundred and seventy-two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate profile page.
When can SAXENDA (liraglutide recombinant) generic drug versions launch?
Generic name: liraglutide recombinant
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2023
Generic Entry Controlled by: South Korea Patent 101,243,648
This drug has two hundred and seventy-five patent family members in thirty-two countries. There has been litigation on patents covering SAXENDA
See drug price trends for SAXENDA.
The generic ingredient in SAXENDA is liraglutide recombinant. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the liraglutide recombinant profile page.
When can SAXENDA (liraglutide recombinant) generic drug versions launch?
Generic name: liraglutide recombinant
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2023
Generic Entry Controlled by: South Korea Patent 20,060,100,428
Patent Title: PROPYLENE GLYCOL-CONTAINING PEPTIDE FORMULATIONS WHICH ARE OPTIMAL FOR PRODUCTION AND FOR USE IN INJECTION DEVICES
This drug has two hundred and seventy-five patent family members in thirty-two countries. There has been litigation on patents covering SAXENDA
See drug price trends for SAXENDA.
The generic ingredient in SAXENDA is liraglutide recombinant. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the liraglutide recombinant profile page.
When can VICTOZA (liraglutide recombinant) generic drug versions launch?
Generic name: liraglutide recombinant
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2023
Generic Entry Controlled by: South Korea Patent 101,243,648
This drug has one hundred and eighty-six patent family members in thirty-two countries. There has been litigation on patents covering VICTOZA
See drug price trends for VICTOZA.
The generic ingredient in VICTOZA is liraglutide recombinant. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the liraglutide recombinant profile page.
When can VICTOZA (liraglutide recombinant) generic drug versions launch?
Generic name: liraglutide recombinant
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2023
Generic Entry Controlled by: South Korea Patent 20,060,100,428
Patent Title: PROPYLENE GLYCOL-CONTAINING PEPTIDE FORMULATIONS WHICH ARE OPTIMAL FOR PRODUCTION AND FOR USE IN INJECTION DEVICES
This drug has one hundred and eighty-six patent family members in thirty-two countries. There has been litigation on patents covering VICTOZA
See drug price trends for VICTOZA.
The generic ingredient in VICTOZA is liraglutide recombinant. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the liraglutide recombinant profile page.
When can XARELTO (rivaroxaban) generic drug versions launch?
Generic name: rivaroxaban
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2023
Generic Entry Controlled by: South Korea Patent 101,151,117
This drug has one hundred and fifty-six patent family members in forty-seven countries. There has been litigation on patents covering XARELTO
See drug price trends for XARELTO.
The generic ingredient in XARELTO is rivaroxaban. There are thirty-five drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the rivaroxaban profile page.
When can XARELTO (rivaroxaban) generic drug versions launch?
Generic name: rivaroxaban
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2023
Generic Entry Controlled by: South Korea Patent 20,060,117,330
Patent Title: METHOD FOR THE PRODUCTION OF A SOLID, ORALLY APPLICABLE PHARMACEUTICAL COMPOSITION
This drug has one hundred and fifty-six patent family members in forty-seven countries. There has been litigation on patents covering XARELTO
See drug price trends for XARELTO.
The generic ingredient in XARELTO is rivaroxaban. There are thirty-five drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the rivaroxaban profile page.
When can VYZULTA (latanoprostene bunod) generic drug versions launch?
Generic name: latanoprostene bunod
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 05, 2024
Generic Entry Controlled by: South Korea Patent 100,850,133
This drug has fifty-three patent family members in thirty-eight countries.
See drug price trends for VYZULTA.
The generic ingredient in VYZULTA is latanoprostene bunod. One supplier is listed for this generic product. Additional details are available on the latanoprostene bunod profile page.
When can VYZULTA (latanoprostene bunod) generic drug versions launch?
Generic name: latanoprostene bunod
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 05, 2024
Generic Entry Controlled by: South Korea Patent 100,854,838
This drug has fifty-three patent family members in thirty-eight countries.
See drug price trends for VYZULTA.
The generic ingredient in VYZULTA is latanoprostene bunod. One supplier is listed for this generic product. Additional details are available on the latanoprostene bunod profile page.
When can VYZULTA (latanoprostene bunod) generic drug versions launch?
Generic name: latanoprostene bunod
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 05, 2024
Generic Entry Controlled by: South Korea Patent 20,060,113,753
Patent Title: PROSTAGLANDIN NITROOXYDERIVATIVES
This drug has fifty-three patent family members in thirty-eight countries.
See drug price trends for VYZULTA.
The generic ingredient in VYZULTA is latanoprostene bunod. One supplier is listed for this generic product. Additional details are available on the latanoprostene bunod profile page.
When can VYZULTA (latanoprostene bunod) generic drug versions launch?
Generic name: latanoprostene bunod
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 05, 2024
Generic Entry Controlled by: South Korea Patent 20,080,007,415
Patent Title: PROSTAGLANDIN NITROOXYDERIVATIVES
This drug has fifty-three patent family members in thirty-eight countries.
See drug price trends for VYZULTA.
The generic ingredient in VYZULTA is latanoprostene bunod. One supplier is listed for this generic product. Additional details are available on the latanoprostene bunod profile page.
When can NAMZARIC (donepezil hydrochloride; memantine hydrochloride) generic drug versions launch?
Generic name: donepezil hydrochloride; memantine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 29, 2024
Generic Entry Controlled by: South Korea Patent 101,301,429
This drug has sixty-seven patent family members in nineteen countries. There has been litigation on patents covering NAMZARIC
See drug price trends for NAMZARIC.
The generic ingredient in NAMZARIC is donepezil hydrochloride; memantine hydrochloride. There are thirty-two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the donepezil hydrochloride; memantine hydrochloride profile page.
When can NAMZARIC (donepezil hydrochloride; memantine hydrochloride) generic drug versions launch?
Generic name: donepezil hydrochloride; memantine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 29, 2024
Generic Entry Controlled by: South Korea Patent 101,406,456
This drug has sixty-seven patent family members in nineteen countries. There has been litigation on patents covering NAMZARIC
See drug price trends for NAMZARIC.
The generic ingredient in NAMZARIC is donepezil hydrochloride; memantine hydrochloride. There are thirty-two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the donepezil hydrochloride; memantine hydrochloride profile page.
When can NAMZARIC (donepezil hydrochloride; memantine hydrochloride) generic drug versions launch?
Generic name: donepezil hydrochloride; memantine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 29, 2024
Generic Entry Controlled by: South Korea Patent 20,060,124,731
Patent Title: COMBINATION OF A NMDA RECEPTOR ANTAGONIST AND A MAO-INHIBITOR OR A GADPH-INHIBITOR FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM-RELATED CONDITIONS
This drug has sixty-seven patent family members in nineteen countries. There has been litigation on patents covering NAMZARIC
See drug price trends for NAMZARIC.
The generic ingredient in NAMZARIC is donepezil hydrochloride; memantine hydrochloride. There are thirty-two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the donepezil hydrochloride; memantine hydrochloride profile page.
When can NAMZARIC (donepezil hydrochloride; memantine hydrochloride) generic drug versions launch?
Generic name: donepezil hydrochloride; memantine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 29, 2024
Generic Entry Controlled by: South Korea Patent 20,070,112,763
Patent Title: COMPOSITION COMPRISING A SUSTAINED RELEASE COATING OR MATRIX AND AN NMDA RECEPTOR ANTAGONIST, METHOD FOR ADMINISTRATION SUCH NMDA ANTAGONIST TO A SUBJECT
This drug has sixty-seven patent family members in nineteen countries. There has been litigation on patents covering NAMZARIC
See drug price trends for NAMZARIC.
The generic ingredient in NAMZARIC is donepezil hydrochloride; memantine hydrochloride. There are thirty-two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the donepezil hydrochloride; memantine hydrochloride profile page.
When can NAMZARIC (donepezil hydrochloride; memantine hydrochloride) generic drug versions launch?
Generic name: donepezil hydrochloride; memantine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 29, 2024
Generic Entry Controlled by: South Korea Patent 20,070,116,996
Patent Title: METHODS AND COMPOSITIONS FOR TREATMENT OF CNS DISORDERS
This drug has sixty-seven patent family members in nineteen countries. There has been litigation on patents covering NAMZARIC
See drug price trends for NAMZARIC.
The generic ingredient in NAMZARIC is donepezil hydrochloride; memantine hydrochloride. There are thirty-two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the donepezil hydrochloride; memantine hydrochloride profile page.
When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch?
Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 30, 2024
Generic Entry Controlled by: South Korea Patent 101,331,768
ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty-one patents protecting this drug.
This drug has four hundred and forty-nine patent family members in thirty-five countries.
See drug price trends for ORKAMBI.
The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.
When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch?
Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 30, 2024
Generic Entry Controlled by: South Korea Patent 101,561,482
ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty-one patents protecting this drug.
This drug has four hundred and forty-nine patent family members in thirty-five countries.
See drug price trends for ORKAMBI.
The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.
When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch?
Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 30, 2024
Generic Entry Controlled by: South Korea Patent 20,080,066,086
Patent Title: HETEROCYCLIC MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS
ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty-one patents protecting this drug.
This drug has four hundred and forty-nine patent family members in thirty-five countries.
See drug price trends for ORKAMBI.
The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.
When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch?
Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 30, 2024
Generic Entry Controlled by: South Korea Patent 20,130,034,062
Patent Title: HETEROCYCLIC MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS
ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty-one patents protecting this drug.
This drug has four hundred and forty-nine patent family members in thirty-five countries.
See drug price trends for ORKAMBI.
The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.
When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch?
Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 30, 2024
Generic Entry Controlled by: South Korea Patent 20,130,042,034
Patent Title: HETEROCYCLIC MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS
ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty-one patents protecting this drug.
This drug has four hundred and forty-nine patent family members in thirty-five countries.
See drug price trends for ORKAMBI.
The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.
When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch?
Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 30, 2024
Generic Entry Controlled by: South Korea Patent 20,140,009,566
Patent Title: HETEROCYCLIC MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS
ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty-one patents protecting this drug.
This drug has four hundred and forty-nine patent family members in thirty-five countries.
See drug price trends for ORKAMBI.
The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.
When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch?
Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 30, 2024
Generic Entry Controlled by: South Korea Patent 20,150,041,174
Patent Title: ＡＴＰ 결합 카세트 수송체의 헤테로사이클릭 조정제 (Heterocyclic modulators of ATP-binding cassette transporters)
ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty-one patents protecting this drug.
This drug has four hundred and forty-nine patent family members in thirty-five countries.
See drug price trends for ORKAMBI.
The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.
When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch?
Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 30, 2024
Generic Entry Controlled by: South Korea Patent 20,160,067,985
Patent Title: ＡＴＰ 결합 카세트 수송체의 헤테로사이클릭 조정제 (HETEROCYCLIC MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS)
ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty-one patents protecting this drug.
This drug has four hundred and forty-nine patent family members in thirty-five countries.
See drug price trends for ORKAMBI.
The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.
When can EPANOVA (omega-3-carboxylic acids) generic drug versions launch?
Generic name: omega-3-carboxylic acids
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 13, 2024
Generic Entry Controlled by: South Korea Patent 101,198,458
EPANOVA is a drug marketed by Astrazeneca. There are seven patents protecting this drug.
This drug has eighty-four patent family members in forty countries.
The generic ingredient in EPANOVA is omega-3-carboxylic acids. There is one drug master file entry for this API. Additional details are available on the omega-3-carboxylic acids profile page.
When can EPANOVA (omega-3-carboxylic acids) generic drug versions launch?
Generic name: omega-3-carboxylic acids
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 13, 2024
Generic Entry Controlled by: South Korea Patent 20,070,011,307
Patent Title: SOFT GELATIN CAPSULE COMPRISING OMEGA-3-POLYUNSATURATED FATTY ACID
EPANOVA is a drug marketed by Astrazeneca. There are seven patents protecting this drug.
This drug has eighty-four patent family members in forty countries.
The generic ingredient in EPANOVA is omega-3-carboxylic acids. There is one drug master file entry for this API. Additional details are available on the omega-3-carboxylic acids profile page.
When can JUXTAPID (lomitapide mesylate) generic drug versions launch?
Generic name: lomitapide mesylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 05, 2024
Generic Entry Controlled by: South Korea Patent 101,494,067
JUXTAPID is a drug marketed by Amryt. There are eight patents protecting this drug.
This drug has twenty-seven patent family members in eighteen countries. There has been litigation on patents covering JUXTAPID
See drug price trends for JUXTAPID.
The generic ingredient in JUXTAPID is lomitapide mesylate. There are two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the lomitapide mesylate profile page.
When can JUXTAPID (lomitapide mesylate) generic drug versions launch?
Generic name: lomitapide mesylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 05, 2024
Generic Entry Controlled by: South Korea Patent 20,060,129,082
Patent Title: METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE-EFFECTS
JUXTAPID is a drug marketed by Amryt. There are eight patents protecting this drug.
This drug has twenty-seven patent family members in eighteen countries. There has been litigation on patents covering JUXTAPID
See drug price trends for JUXTAPID.
The generic ingredient in JUXTAPID is lomitapide mesylate. There are two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the lomitapide mesylate profile page.
When can JUXTAPID (lomitapide mesylate) generic drug versions launch?
Generic name: lomitapide mesylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 05, 2024
Generic Entry Controlled by: South Korea Patent 20,130,004,942
Patent Title: METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE-EFFECTS
JUXTAPID is a drug marketed by Amryt. There are eight patents protecting this drug.
This drug has twenty-seven patent family members in eighteen countries. There has been litigation on patents covering JUXTAPID
See drug price trends for JUXTAPID.
The generic ingredient in JUXTAPID is lomitapide mesylate. There are two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the lomitapide mesylate profile page.
When can RUKOBIA (fostemsavir tromethamine) generic drug versions launch?
Generic name: fostemsavir tromethamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 15, 2024
Generic Entry Controlled by: South Korea Patent 101,153,594
RUKOBIA is a drug marketed by Viiv Hlthcare. There are three patents protecting this drug.
This drug has thirty-nine patent family members in thirty countries.
See drug price trends for RUKOBIA.
The generic ingredient in RUKOBIA is fostemsavir tromethamine. One supplier is listed for this generic product. Additional details are available on the fostemsavir tromethamine profile page.
When can RUKOBIA (fostemsavir tromethamine) generic drug versions launch?
Generic name: fostemsavir tromethamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 15, 2024
Generic Entry Controlled by: South Korea Patent 20,060,129,533
Patent Title: PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS
RUKOBIA is a drug marketed by Viiv Hlthcare. There are three patents protecting this drug.
This drug has thirty-nine patent family members in thirty countries.
See drug price trends for RUKOBIA.
The generic ingredient in RUKOBIA is fostemsavir tromethamine. One supplier is listed for this generic product. Additional details are available on the fostemsavir tromethamine profile page.
When can SYNJARDY (empagliflozin; metformin hydrochloride) generic drug versions launch?
Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: South Korea Patent 101,174,726
This drug has two hundred and twenty-one patent family members in forty-four countries. There has been litigation on patents covering SYNJARDY
See drug price trends for SYNJARDY.
The generic ingredient in SYNJARDY is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.
When can SYNJARDY (empagliflozin; metformin hydrochloride) generic drug versions launch?
Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: South Korea Patent 20,060,133,021
Patent Title: GLUCOPYRANOSYL-SUBSTITUTED BENZOL DERIVATIVES, DRUGS CONTAINING SAID COMPOUNDS, THE USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF
This drug has two hundred and twenty-one patent family members in forty-four countries. There has been litigation on patents covering SYNJARDY
See drug price trends for SYNJARDY.
The generic ingredient in SYNJARDY is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.
When can SYNJARDY (empagliflozin; metformin hydrochloride) generic drug versions launch?
Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: South Korea Patent 20,120,007,088
Patent Title: GLUCOPYRANOSYL-SUBSTITUTED BENZOL DERIVATIVES, DRUGS CONTAINING SAID COMPOUNDS, THE USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF
This drug has two hundred and twenty-one patent family members in forty-four countries. There has been litigation on patents covering SYNJARDY
See drug price trends for SYNJARDY.
The generic ingredient in SYNJARDY is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.
When can SYNJARDY XR (empagliflozin; metformin hydrochloride) generic drug versions launch?
Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: South Korea Patent 101,174,726
This drug has one hundred and ninety-five patent family members in forty countries. There has been litigation on patents covering SYNJARDY XR
See drug price trends for SYNJARDY XR.
The generic ingredient in SYNJARDY XR is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.
When can SYNJARDY XR (empagliflozin; metformin hydrochloride) generic drug versions launch?
Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: South Korea Patent 20,060,133,021
Patent Title: GLUCOPYRANOSYL-SUBSTITUTED BENZOL DERIVATIVES, DRUGS CONTAINING SAID COMPOUNDS, THE USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF
This drug has one hundred and ninety-five patent family members in forty countries. There has been litigation on patents covering SYNJARDY XR
See drug price trends for SYNJARDY XR.
The generic ingredient in SYNJARDY XR is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.
When can SYNJARDY XR (empagliflozin; metformin hydrochloride) generic drug versions launch?
Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: South Korea Patent 20,120,007,088
Patent Title: GLUCOPYRANOSYL-SUBSTITUTED BENZOL DERIVATIVES, DRUGS CONTAINING SAID COMPOUNDS, THE USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF
This drug has one hundred and ninety-five patent family members in forty countries. There has been litigation on patents covering SYNJARDY XR
See drug price trends for SYNJARDY XR.
The generic ingredient in SYNJARDY XR is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.
When can TEKTURNA (aliskiren hemifumarate) generic drug versions launch?
Generic name: aliskiren hemifumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 17, 2024
Generic Entry Controlled by: South Korea Patent 101,274,855
This drug has forty patent family members in twenty-two countries. There has been litigation on patents covering TEKTURNA
See drug price trends for TEKTURNA.
The generic ingredient in TEKTURNA is aliskiren hemifumarate. There are four drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the aliskiren hemifumarate profile page.
When can TEKTURNA (aliskiren hemifumarate) generic drug versions launch?
Generic name: aliskiren hemifumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 17, 2024
Generic Entry Controlled by: South Korea Patent 101,353,736
This drug has forty patent family members in twenty-two countries. There has been litigation on patents covering TEKTURNA
See drug price trends for TEKTURNA.
The generic ingredient in TEKTURNA is aliskiren hemifumarate. There are four drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the aliskiren hemifumarate profile page.
When can TEKTURNA (aliskiren hemifumarate) generic drug versions launch?
Generic name: aliskiren hemifumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 17, 2024
Generic Entry Controlled by: South Korea Patent 20,070,006,776
Patent Title: GALENIC FORMULATIONS OF ORGANIC COMPOUNDS
This drug has forty patent family members in twenty-two countries. There has been litigation on patents covering TEKTURNA
See drug price trends for TEKTURNA.
The generic ingredient in TEKTURNA is aliskiren hemifumarate. There are four drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the aliskiren hemifumarate profile page.
When can TEKTURNA (aliskiren hemifumarate) generic drug versions launch?
Generic name: aliskiren hemifumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 17, 2024
Generic Entry Controlled by: South Korea Patent 20,130,028,803
Patent Title: GALENIC FORMULATIONS OF ORGANIC COMPOUNDS
This drug has forty patent family members in twenty-two countries. There has been litigation on patents covering TEKTURNA
See drug price trends for TEKTURNA.
The generic ingredient in TEKTURNA is aliskiren hemifumarate. There are four drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the aliskiren hemifumarate profile page.
When can IMPLANON (etonogestrel) generic drug versions launch?
Generic name: etonogestrel
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 19, 2024
Generic Entry Controlled by: South Korea Patent 101,086,619
IMPLANON is a drug marketed by Organon. There is one patent protecting this drug.
This drug has thirty-two patent family members in twenty-six countries.
The generic ingredient in IMPLANON is etonogestrel. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the etonogestrel profile page.
When can IMPLANON (etonogestrel) generic drug versions launch?
Generic name: etonogestrel
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 19, 2024
Generic Entry Controlled by: South Korea Patent 20,070,027,530
Patent Title: X-RAY VISIBLE DRUG DELIVERY DEVICE
IMPLANON is a drug marketed by Organon. There is one patent protecting this drug.
This drug has thirty-two patent family members in twenty-six countries.
The generic ingredient in IMPLANON is etonogestrel. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the etonogestrel profile page.
When can FORTEO (teriparatide recombinant human) generic drug versions launch?
Generic name: teriparatide recombinant human
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 30, 2024
Generic Entry Controlled by: South Korea Patent 100,763,051
This drug has thirty-seven patent family members in twenty-five countries. There has been litigation on patents covering FORTEO
See drug price trends for FORTEO.
The generic ingredient in FORTEO is teriparatide recombinant human. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the teriparatide recombinant human profile page.
When can FORTEO (teriparatide recombinant human) generic drug versions launch?
Generic name: teriparatide recombinant human
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 30, 2024
Generic Entry Controlled by: South Korea Patent 20,060,131,946
Patent Title: MEDICATION DISPENSING APPARATUS WITH SPRING-DRIVEN LOCKING FEATURE ENABLED BY ADMINISTRATION OF FINAL DOSE
This drug has thirty-seven patent family members in twenty-five countries. There has been litigation on patents covering FORTEO
See drug price trends for FORTEO.
The generic ingredient in FORTEO is teriparatide recombinant human. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the teriparatide recombinant human profile page.
When can DUAVEE (bazedoxifene acetate; estrogens, conjugated) generic drug versions launch?
Generic name: bazedoxifene acetate; estrogens, conjugated
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 07, 2024
Generic Entry Controlled by: South Korea Patent 20,060,135,866
Patent Title: CRYSTALLINE POLYMORPH OF A BAZEDOXIFENE ACETATE
This drug has twenty-two patent family members in twenty countries.
See drug price trends for DUAVEE.
The generic ingredient in DUAVEE is bazedoxifene acetate; estrogens, conjugated. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the bazedoxifene acetate; estrogens, conjugated profile page.
When can NATAZIA (dienogest; estradiol valerate) generic drug versions launch?
Generic name: dienogest; estradiol valerate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 20, 2024
Generic Entry Controlled by: South Korea Patent 20,060,134,168
Patent Title: MULTI-PHASE CONTRACEPTIVE PREPARATION BASED ON A NATURAL ESTROGEN
This drug has ninety patent family members in thirty-nine countries. There has been litigation on patents covering NATAZIA
See drug price trends for NATAZIA.
The generic ingredient in NATAZIA is dienogest; estradiol valerate. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the dienogest; estradiol valerate profile page.
When can INCRUSE ELLIPTA (umeclidinium bromide) generic drug versions launch?
Generic name: umeclidinium bromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 27, 2024
Generic Entry Controlled by: South Korea Patent 101,037,026
This drug has one hundred and seventy-seven patent family members in thirty-nine countries.
See drug price trends for INCRUSE ELLIPTA .
The generic ingredient in INCRUSE ELLIPTA is umeclidinium bromide. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the umeclidinium bromide profile page.
When can INCRUSE ELLIPTA (umeclidinium bromide) generic drug versions launch?
Generic name: umeclidinium bromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 27, 2024
Generic Entry Controlled by: South Korea Patent 101,152,032
This drug has one hundred and seventy-seven patent family members in thirty-nine countries.
See drug price trends for INCRUSE ELLIPTA .
The generic ingredient in INCRUSE ELLIPTA is umeclidinium bromide. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the umeclidinium bromide profile page.
When can INCRUSE ELLIPTA (umeclidinium bromide) generic drug versions launch?
Generic name: umeclidinium bromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 27, 2024
Generic Entry Controlled by: South Korea Patent 20,070,015,412
Patent Title: MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS
This drug has one hundred and seventy-seven patent family members in thirty-nine countries.
See drug price trends for INCRUSE ELLIPTA .
The generic ingredient in INCRUSE ELLIPTA is umeclidinium bromide. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the umeclidinium bromide profile page.
When can INCRUSE ELLIPTA (umeclidinium bromide) generic drug versions launch?
Generic name: umeclidinium bromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 27, 2024
Generic Entry Controlled by: South Korea Patent 20,110,010,841
Patent Title: MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS
This drug has one hundred and seventy-seven patent family members in thirty-nine countries.
See drug price trends for INCRUSE ELLIPTA .
The generic ingredient in INCRUSE ELLIPTA is umeclidinium bromide. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the umeclidinium bromide profile page.
When can VIZIMPRO (dacomitinib) generic drug versions launch?
Generic name: dacomitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 06, 2024
Generic Entry Controlled by: South Korea Patent 100,885,835
VIZIMPRO is a drug marketed by Pfizer. There are four patents protecting this drug.
This drug has ninety-two patent family members in forty-eight countries.
See drug price trends for VIZIMPRO.
The generic ingredient in VIZIMPRO is dacomitinib. Two suppliers are listed for this generic product. Additional details are available on the dacomitinib profile page.
When can VIZIMPRO (dacomitinib) generic drug versions launch?
Generic name: dacomitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 06, 2024
Generic Entry Controlled by: South Korea Patent 20,070,008,683
Patent Title: 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES
VIZIMPRO is a drug marketed by Pfizer. There are four patents protecting this drug.
This drug has ninety-two patent family members in forty-eight countries.
See drug price trends for VIZIMPRO.
The generic ingredient in VIZIMPRO is dacomitinib. Two suppliers are listed for this generic product. Additional details are available on the dacomitinib profile page.
When can VIZIMPRO (dacomitinib) generic drug versions launch?
Generic name: dacomitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 06, 2024
Generic Entry Controlled by: South Korea Patent 20,080,095,915
Patent Title: 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES
VIZIMPRO is a drug marketed by Pfizer. There are four patents protecting this drug.
This drug has ninety-two patent family members in forty-eight countries.
See drug price trends for VIZIMPRO.
The generic ingredient in VIZIMPRO is dacomitinib. Two suppliers are listed for this generic product. Additional details are available on the dacomitinib profile page.
When can KYPROLIS (carfilzomib) generic drug versions launch?
Generic name: carfilzomib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 10, 2024
Generic Entry Controlled by: South Korea Patent 101,299,821
KYPROLIS is a drug marketed by Onyx Pharms Amgen. There are twelve patents protecting this drug and three Paragraph IV challenges. Four tentatively approved generics are ready to enter the market.
This drug has two hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering KYPROLIS
See drug price trends for KYPROLIS.
The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.
When can KYPROLIS (carfilzomib) generic drug versions launch?
Generic name: carfilzomib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 10, 2024
Generic Entry Controlled by: South Korea Patent 20,070,086,924
Patent Title: COMPOSITION FOR PROTEASOME INHIBITION
KYPROLIS is a drug marketed by Onyx Pharms Amgen. There are twelve patents protecting this drug and three Paragraph IV challenges. Four tentatively approved generics are ready to enter the market.
This drug has two hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering KYPROLIS
See drug price trends for KYPROLIS.
The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.
When can ARCAPTA NEOHALER (indacaterol maleate) generic drug versions launch?
Generic name: indacaterol maleate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2024
Generic Entry Controlled by: South Korea Patent 101,170,187
This drug has eighty-six patent family members in thirty-nine countries. There has been litigation on patents covering ARCAPTA NEOHALER
See drug price trends for ARCAPTA NEOHALER.
The generic ingredient in ARCAPTA NEOHALER is indacaterol maleate. Additional details are available on the indacaterol maleate profile page.
When can ARCAPTA NEOHALER (indacaterol maleate) generic drug versions launch?
Generic name: indacaterol maleate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2024
Generic Entry Controlled by: South Korea Patent 20,070,011,466
Patent Title: INHALER DEVICE
This drug has eighty-six patent family members in thirty-nine countries. There has been litigation on patents covering ARCAPTA NEOHALER
See drug price trends for ARCAPTA NEOHALER.
The generic ingredient in ARCAPTA NEOHALER is indacaterol maleate. Additional details are available on the indacaterol maleate profile page.
When can UTIBRON (glycopyrrolate ; indacaterol maleate) generic drug versions launch?
Generic name: glycopyrrolate ; indacaterol maleate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2024
Generic Entry Controlled by: South Korea Patent 101,170,187
UTIBRON is a drug marketed by Novartis. There are three patents protecting this drug.
This drug has one hundred and forty-eight patent family members in forty countries. There has been litigation on patents covering UTIBRON
See drug price trends for UTIBRON.
The generic ingredient in UTIBRON is glycopyrrolate ; indacaterol maleate. There are seventeen drug master file entries for this API. Additional details are available on the glycopyrrolate ; indacaterol maleate profile page.
When can UTIBRON (glycopyrrolate ; indacaterol maleate) generic drug versions launch?
Generic name: glycopyrrolate ; indacaterol maleate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2024
Generic Entry Controlled by: South Korea Patent 20,070,011,466
Patent Title: INHALER DEVICE
UTIBRON is a drug marketed by Novartis. There are three patents protecting this drug.
This drug has one hundred and forty-eight patent family members in forty countries. There has been litigation on patents covering UTIBRON
See drug price trends for UTIBRON.
The generic ingredient in UTIBRON is glycopyrrolate ; indacaterol maleate. There are seventeen drug master file entries for this API. Additional details are available on the glycopyrrolate ; indacaterol maleate profile page.
When can VITEKTA (elvitegravir) generic drug versions launch?
Generic name: elvitegravir
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 20, 2024
Generic Entry Controlled by: South Korea Patent 20,080,064,909
Patent Title: STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND
VITEKTA is a drug marketed by Gilead Sciences Inc. There are three patents protecting this drug.
This drug has eighty-three patent family members in thirty-five countries. There has been litigation on patents covering VITEKTA
The generic ingredient in VITEKTA is elvitegravir. There are six drug master file entries for this API. Additional details are available on the elvitegravir profile page.
When can CAPRELSA (vandetanib) generic drug versions launch?
Generic name: vandetanib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 21, 2024
Generic Entry Controlled by: South Korea Patent 101,192,935
CAPRELSA is a drug marketed by Genzyme Corp. There is one patent protecting this drug.
This drug has forty patent family members in thirty-three countries.
See drug price trends for CAPRELSA.
The generic ingredient in CAPRELSA is vandetanib. One supplier is listed for this generic product. Additional details are available on the vandetanib profile page.
When can CAPRELSA (vandetanib) generic drug versions launch?
Generic name: vandetanib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 21, 2024
Generic Entry Controlled by: South Korea Patent 20,070,034,499
CAPRELSA is a drug marketed by Genzyme Corp. There is one patent protecting this drug.
This drug has forty patent family members in thirty-three countries.
See drug price trends for CAPRELSA.
The generic ingredient in CAPRELSA is vandetanib. One supplier is listed for this generic product. Additional details are available on the vandetanib profile page.
When can KOMBIGLYZE XR (metformin hydrochloride; saxagliptin hydrochloride) generic drug versions launch?
Generic name: metformin hydrochloride; saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: South Korea Patent 101,290,925
This drug has one hundred and twenty-seven patent family members in forty-one countries. There has been litigation on patents covering KOMBIGLYZE XR
See drug price trends for KOMBIGLYZE XR.
The generic ingredient in KOMBIGLYZE XR is metformin hydrochloride; saxagliptin hydrochloride. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; saxagliptin hydrochloride profile page.
When can KOMBIGLYZE XR (metformin hydrochloride; saxagliptin hydrochloride) generic drug versions launch?
Generic name: metformin hydrochloride; saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: South Korea Patent 20,070,027,560
Patent Title: COATED TABLET FORMULATION AND METHOD
This drug has one hundred and twenty-seven patent family members in forty-one countries. There has been litigation on patents covering KOMBIGLYZE XR
See drug price trends for KOMBIGLYZE XR.
The generic ingredient in KOMBIGLYZE XR is metformin hydrochloride; saxagliptin hydrochloride. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; saxagliptin hydrochloride profile page.
When can KOMBIGLYZE XR (metformin hydrochloride; saxagliptin hydrochloride) generic drug versions launch?
Generic name: metformin hydrochloride; saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: South Korea Patent 20,120,064,141
Patent Title: COATED TABLET FORMULATION AND METHOD
This drug has one hundred and twenty-seven patent family members in forty-one countries. There has been litigation on patents covering KOMBIGLYZE XR
See drug price trends for KOMBIGLYZE XR.
The generic ingredient in KOMBIGLYZE XR is metformin hydrochloride; saxagliptin hydrochloride. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; saxagliptin hydrochloride profile page.
When can ONGLYZA (saxagliptin hydrochloride) generic drug versions launch?
Generic name: saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: South Korea Patent 101,290,925
This drug has one hundred and twenty-seven patent family members in forty-one countries. There has been litigation on patents covering ONGLYZA
See drug price trends for ONGLYZA.
The generic ingredient in ONGLYZA is saxagliptin hydrochloride. There are fifteen drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the saxagliptin hydrochloride profile page.
When can ONGLYZA (saxagliptin hydrochloride) generic drug versions launch?
Generic name: saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: South Korea Patent 20,070,027,560
Patent Title: COATED TABLET FORMULATION AND METHOD
This drug has one hundred and twenty-seven patent family members in forty-one countries. There has been litigation on patents covering ONGLYZA
See drug price trends for ONGLYZA.
The generic ingredient in ONGLYZA is saxagliptin hydrochloride. There are fifteen drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the saxagliptin hydrochloride profile page.
When can ONGLYZA (saxagliptin hydrochloride) generic drug versions launch?
Generic name: saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: South Korea Patent 20,120,064,141
Patent Title: COATED TABLET FORMULATION AND METHOD
This drug has one hundred and twenty-seven patent family members in forty-one countries. There has been litigation on patents covering ONGLYZA
See drug price trends for ONGLYZA.
The generic ingredient in ONGLYZA is saxagliptin hydrochloride. There are fifteen drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the saxagliptin hydrochloride profile page.
When can FOLOTYN (pralatrexate) generic drug versions launch?
Generic name: pralatrexate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 30, 2024
Generic Entry Controlled by: South Korea Patent 101,189,692
FOLOTYN is a drug marketed by Acrotech Biopharma. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has thirty-one patent family members in twenty-three countries. There has been litigation on patents covering FOLOTYN
See drug price trends for FOLOTYN.
The generic ingredient in FOLOTYN is pralatrexate. There are two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the pralatrexate profile page.